IKNA vs. TSBX, CDTX, TARA, GNTA, AVRO, LENZ, ENTX, ATRA, CVM, and ALGS
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Turnstone Biologics (TSBX), Cidara Therapeutics (CDTX), Protara Therapeutics (TARA), Genenta Science (GNTA), AVROBIO (AVRO), LENZ Therapeutics (LENZ), Entera Bio (ENTX), Atara Biotherapeutics (ATRA), CEL-SCI (CVM), and Aligos Therapeutics (ALGS). These companies are all part of the "biological products, except diagnostic" industry.
Turnstone Biologics (NASDAQ:TSBX) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
Turnstone Biologics has higher revenue and earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ikena Oncology had 5 more articles in the media than Turnstone Biologics. MarketBeat recorded 11 mentions for Ikena Oncology and 6 mentions for Turnstone Biologics. Turnstone Biologics' average media sentiment score of 0.80 beat Ikena Oncology's score of -0.34 indicating that Ikena Oncology is being referred to more favorably in the news media.
Ikena Oncology received 25 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 60.00% of users gave Ikena Oncology an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote.
52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by insiders. Comparatively, 6.0% of Ikena Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Turnstone Biologics' return on equity of -42.04% beat Ikena Oncology's return on equity.
Turnstone Biologics currently has a consensus target price of $19.00, suggesting a potential upside of 595.97%. Ikena Oncology has a consensus target price of $9.50, suggesting a potential upside of 578.57%. Given Ikena Oncology's higher possible upside, equities research analysts clearly believe Turnstone Biologics is more favorable than Ikena Oncology.
Summary
Ikena Oncology beats Turnstone Biologics on 11 of the 16 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ikena Oncology Competitors List
Related Companies and Tools
